B+
Bull case
25%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
VRDN
Viridian TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-04
Recent news sentiment (30D)
+72.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+75.0
Score
AI commentary
Headline tone is positive following FDA approval, Lumvoa's U.S. launch, and the Q2 update. Social, options, short-interest, employee-sentiment, analyst-revision, and post-print price-reaction data are unavailable; the evidence supports a positive but execution-dependent monitoring view rather than high conviction.
RankAlpha Sentiment Codex - 2026-09-04
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-03eventFcRn and TSHR development milestonesHigh impact
VRDN-008 phase 1 healthy-volunteer data are expected in 2H 2026, with a TSHR IND submission anticipated in Q4 2026 and additional FcRn development updates planned. Timing and outcomes remain uncertain. [#SEC-8K-2026-08-06]
2026-12-03catalystLumvoa commercial uptake and payer validationHigh impact
The U.S. launch is the key near-term execution test. Viridian reported first doses in July, engagement with 95% of its 2,000 core prescribing physicians, payer-coverage efforts on track, and strong physician demand in enrollment forms. [#SEC-8K-2026-08-06]
2027-09-04catalystElegrobart BLA submissionHigh impact
Viridian states that a BLA submission for subcutaneous elegrobart remains on track for Q1 2027 following positive topline results from the REVEAL-1 and REVEAL-2 phase 3 trials. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-04 • Updated nightlySource: Internal modelMethodology